Cargando…
A BRD4 PROTAC nanodrug for glioma therapy via the intervention of tumor cells proliferation, apoptosis and M2 macrophages polarization
Glioma is a primary aggressive brain tumor with high recurrence rate. The poor efficiency of chemotherapeutic drugs crossing the blood‒brain barrier (BBB) is well-known as one of the main challenges for anti-glioma therapy. Moreover, massive infiltrated tumor-associated macrophages (TAMs) in glioma...
Autores principales: | Yang, Tingting, Hu, Yuzhu, Miao, Junming, Chen, Jing, Liu, Jiagang, Cheng, Yongzhong, Gao, Xiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214068/ https://www.ncbi.nlm.nih.gov/pubmed/35755286 http://dx.doi.org/10.1016/j.apsb.2022.02.009 |
Ejemplares similares
-
Enhanced anti-glioma efficacy of doxorubicin with BRD4 PROTAC degrader using targeted nanoparticles
por: He, Yihong, et al.
Publicado: (2022) -
BRD4-targeting PROTAC as a unique tool to study biomolecular condensates
por: Shi, Yi, et al.
Publicado: (2023) -
Antibody–PROTAC Conjugates Enable HER2-Dependent
Targeted Protein Degradation of BRD4
por: Maneiro, María, et al.
Publicado: (2020) -
The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells
por: Qin, An-cheng, et al.
Publicado: (2020) -
Lethal activity of BRD4 PROTAC degrader QCA570 against bladder cancer cells
por: Wang, Qiang, et al.
Publicado: (2023)